Morphotek, Inc. (Morphotek)

Oncology Corporate Profile

HQ Location

210 Welsh Pool Road
Exton, PA 19341

Company Description

Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease.

Website: http://www.morphotek.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
farletuzumab / MORAb-003IgG1 monoclonal antibody (humanized)2nd line metastatic Ovarian cancerIIIEisai Inc.
MORAb-004IgG1 monoclonal antibody1st line metastatic MelanomaIIEisai Inc.
MORAb-004IgG1 monoclonal antibody1st line metastatic soft tissue SarcomaIEisai Inc.
MORab-066IgG1 monoclonal antibodyVarious cancer typesIEisai Inc.
MORAb-004IgG1 monoclonal antibodyVarious cancer typesIEisai Inc.
MORAb-009IgG1 monoclonal antibody (humanized)Various cancer typesIEisai Inc.
farletuzumab / MORAb-003IgG1 monoclonal antibody (humanized)Non Small Cell Lung Cancer (NSCLC)II Eisai Inc.
farletuzumab / MORAb-003IgG1 monoclonal antibody (humanized)Platinum-sensitive Ovarian cancerII Eisai Inc.

View additional information on product candidates here »

Source


http://www.morphotek.com/

Recent News Headlines

There are no news items to display